Effectiveness on adherence to biological drugs and experience of a pharmaceutical intervention based on CMO model in patients with rheumatic disease (AdhER-2 study)
DOI:
https://doi.org/10.23938/ASSN.1004Keywords:
Treatment adherence and compliance, Rheumatoid arthritis, Psoriatic arthritis, Spondylitis ankylosing, Patient satisfactionAbstract
Background. We aimed to assess the effectiveness on adherence to treatment with biologic disease modifying anti-rheumatic drugs (b-DMARD) and experience with providers of healthcare of a CMO pharmaceutical intervention care model in subjects with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis stratified according to their needs.
Method. Prospective, single-centre randomized controlled study. The study period was eleven months. Non-compliant patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis treated with b-DMARD were included. Patients were randomized to a control (CG) or intervention group (IG) who received regular or the CMO pharmaceutical intervention model treatment, respectively. Baseline and final adherence were determined using medication possession ratio, the Compliance Questionnaire on Rheumatology, and Morisky Medication Adherence Scale. To assess baseline and final patient experience with providers of healthcare we applied the Chronic Patient Experience Assessment Instrument (IEXPAC).
Results. For the IG, one patient (5.6%) was categorized as priority 1, nine (50.0%) as priority 2, and eight (44.4%) as priority 3. Ninety pharmaceutical interventions were carried out (5.1±1.8 interventions / patient). At the end of the study, the IG showed higher frequency of patients who adhered to the pharmaceutical intervention (77.8 vs 18.8%; p=0.002) and higher mean IEXPAC score (7.6±1.3 vs 5.8±1.1; p <0.001) in comparison to the CG.
Conclusion The CMO pharmaceutical intervention model significantly improves patient adherence to b-DMARD and their experience with the providers of healthcare.
Downloads
References
VRIJENS B, DE GEEST S, HUGHES DA, PRZEMYSLAW K, DEMONCEAU J, RUPPAR T, ET AL. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012; 73: 691-705. https://doi.org/10.1111/j.1365-2125.2012.04167.x
BERMEJO-SAN F, BARCELÓ-BRU M, RIBERA-PIBERNAT M, POVEDA-ANDRÉS JL, SANROMÁN-ÁLVAREZ L. Interdisciplinary recommendations document to improve adherence in patients with chronic inflammatory diseases: adhing recommendations. Farm Hosp 2016; 40: 394-411. https://dx.doi.org/10.7399/fh.2016.40.5.10180
NÚÑEZ-RODRÍGUEZ J, GONZÁLEZ-PÉREZ Y, NEBOT-VILLACAMPA MJ, ZAFRA-MORALES R, OBALDIA-ALAÑA MC, CASO-GONZÁLEZ A. Adherencia terapéutica a fármacos biológicos en pacientes con artritis reumatoide, artritis psoriásica y espondilitis anquilosante. (Estudio ADhER-1) Medicina de Familia - SEMERGEN. 2021; 47: 81-90. http://doi.org/doi: 10.1016/j.semerg.2020.06.024
SCHEIMAN-ELAZARY A, DUAN L, SHOURT C, AGRAWAL H, ELLASHOF D, CAMERON-HAY M et al. The rate of adherence to antiarthritis medications and associated factors among patients with rheumatoid arthritis: a systematic literature review and metaanalysis. J Rheumatol 2016; 43: 512-523. https://doi.org/10.3899/jrheum.141371
BHOI P, BESSETTE L, BELL MJ, TKACZYK C, NANTEL F, MASLOVA K. Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative database. BMJ Open 2017; 7: e015872. http://doi.org/http://doi.org/10.1136/bmjopen-2017-015872
HARNETT J, WIEDERKEHR D, GERBER R, GRUBEN D, BOURRET J, KOENIG A. PRIMARY NONADHERENCE, Associated clinical outcomes, and health care resource use among patients with rheumatoid arthritis prescribed treatment with injectable biologic disease-modifying antirheumatic drugs. J Manag Care Spec Pharm 2016; 22: 209-218. http://doi.org/10.18553/jmcp.2016.22.3.209
BARRUETA IBARRA O, MORILLO VERDUGO R. Lo que debes saber sobre la adherencia al tratamiento. Badalona: Euromedice 2017. https://www.sefh.es/bibliotecavirtual/Adherencia2017/libro_ADHERENCIA.pdf
OSHOTSE C, ZULLIG LL, BOSWORTH HB, TU P, LIN C. Self-efficacy and adherence behaviors in rheumatoid arthritis patients. Prev Chronic Dis 2018; 15: e127. http://doi.org/10.5888/pcd15.180218
YAP AF, THIRUMOORTHY T, KWAN YH. Systematic review of the barriers affecting medication adherence in older adults. Geriatr Gerontol Int 2016; 16: 1093-1101. http://doi.org/10.1111/ggi.12616
Impacto económico de la no adherencia en los costes farmacéuticos. 2013. imFarmacias. Barcelona: Publimas Digital, 2022. https://www.imfarmacias.es/noticia/1011/impacto_economico_de_la_no_adherencia_en_los_costes_farmaceuticos.html
CALLEJA HERNÁNDEZ MA, MORILLO VERDUGO R. El modelo CMO en consultas externas de Farmacia Hospitalaria. Badalona: Euromedice, 2016. https://www.sefh.es/sefhpdfs/Libro_CMO.pdf
Sociedad Española de Farmacia Hospitalaria. Modelo de selección y atención farmacéutica de pacientes crónicos. Madrid: SEFH, 2013. http://www.sefh.es/bibliotecavirtual/Cronicos/AF_INFORME_PACIENTE_GESTION_SANITARIA.pdf
Sociedad Española de Farmacia Hospitalaria. Modelo de estratificación y atención farmacéutica para pacientes con enfermedades inflamatorias inmunomediadas. https://www.sefh.es/mapex/images/Modelo-de-Estratificacion-y-Atencion-Farmaceutica-pacientes-enf-inmunomediadas.pdf
MILLER W, ROLLNICK S. Motivational interviewing: preparing people for change. 2ª ed. New York: Guilfor Press, 2002.
ROLLNICK S, KINNERSLEY P, STOTT N. Methods of helping patients with behaviour change. BMJ 1993; 307: 188-190. https://doi.org/10.1136/bmj.307.6897.188
MORILLO-VERDUGO R, MARTINEZ-SESMERO JM, LÁZARO-LÓPEZ A, SÁNCHEZ-RUBIO, J, NAVARRO-AZNÁREZ H, MIGUEL-CASCÓN M. [Development of a risk stratification model for pharmaceutical care in HIV patients. Farm Hosp 2017; 41: 346-356. http://doi.org/10.7399/fh.2017.41.3.10655
DOYLE C, LENNOX L, BELL D. A systematic review of evidence on the links between patient experience and clinical safety and effectiveness. BMJ Open 2013; 3: e001570. http://doi.org/10.1136/bmjopen-2012-001570
VIRONIQUE VERMAAK, N. KATHY BRIFFA ET AL. Evaluation of a disease specific rheumatoid arthritis self-management education program, a single group repeated measures study. BMC Musculoskelet Disord 2015; 16: 214. http://doi.org/10.1186/s12891-015-0663-6
LOFLAND JH, JOHNSON PT, INGHAM MP, ROSEMAS SC, WHITE JC, ELLIS L. Shared decision-making for biologic treatment of autoimmune disease: influence on adherence, persistence, satisfaction, and health care costs. Patient Prefer Adherence 2017; 11: 947-958.
Sociedad Española de Farmacia Hospitalaria (SEFH). Guía de práctica farmacéutica en espondiloartropatías. SEFH. 2019. Disponible en: https://www.sefh.es/sefhjornadas/87_guia_espondiloartropatias.pdf
BLUM MA, KOO D, DOSHI JA. Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic review. Clin Ther. 2011; 33: 901-913. https://doi.org/10.1016/j.clinthera.2011.06.001
DE KLERK E, VAN DER HEIJDE D, LANDEWÉ R, VAN DER TEMPEL H, VAN DER LINDEN S. The compliance-questionnaire-rheumatology compared with electronic medication event monitoring: a validation study. J Rheumatol 2003; 30: 2469-2475.
MORISKY DE, GREEN LW, LEVINE DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986; 24: 67-74. https://doi.org/10.1097/00005650-198601000-00007
Equipo IEMAC (Instrumento de Evaluación de Modelos de Atención ante la Cronicidad). IEXPAC: instrumento de evaluación de la experiencia del paciente crónico. https://www.iemac.es/iexpac/
CANTILLANA-SUÁREZ MG, MANZANO-GARCÍA ME, ROBUSTILLO-CORTÉS MA, MORILLO-VERDUGO R. Evaluación de la experiencia del paciente VIH+ con la AF basada en la metodología CMO. Farm Hosp 2018. 42: 200-203. https://doi.org/10.7399/fh.10947
Asociación Médica Mundial. Declaración de Helsinki. Principios éticos para las investigaciones médicas en seres humanos. 64ª Asamblea General. Fortaleza, Brasil, octubre 2013.
Ley Orgánica 3/2018, de 5 de diciembre, de Protección de Datos Personales y garantía de los derechos digitales. BOE 2018; 294: 119788-119857. https://www.boe.es/eli/es/lo/2018/12/05/3
TAIBANGUAY N, CHAIAMNUAY S, ASAVATANABODEE P, NARONGROEKNAWIN P. Effect of patient education on medication adherence of patients with rheumatoid arthritis: a randomized controlled trial. Patient Prefer Adherence 2019; 13: 119-129. http://doi.org/10.2147/PPA.S192008
MARÍN-JIMÉNEZ I, CASELLAS F, CORTÉS X, GARCÍA-SEPULCRE MF, JULIÁ B, CEA-CALVO L et al. The experience of inflammatory bowel disease patients with healthcare: A survey with the IEXPAC instrument. Medicine (Baltimore) 2019; 98: e15044. https://doi.org/10.1097/MD.0000000000015044
OROZCO-BELTRÁN D, DE TORO J, GALINDO MJ, MARÍN-JIMÉNEZ I, CASELLAS F, FUSTER-RUIZDEAPODACA MJ et al. Healthcare experience and their relationship with demographic, disease and healthcare-related variables: a cross-sectional survey of patients with chronic diseases using the IEXPAC scale. Patient 2019; 12: 307-317. https://doi.org/10.1007/s40271-018-0345-1
DANET A, PRIETO RODRÍGUEZ MA, MARCH CERDÀ JC. La activación de pacientes crónicos y su relación con el personal sanitario en Andalucía. An Sist Sanit Navar 2017; 40: 247-257. http://doi.org/10.23938/assn.0034
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
La revista Anales del Sistema Sanitario de Navarra es publicada por el Departamento de Salud del Gobierno de Navarra (España), quien conserva los derechos patrimoniales (copyright ) sobre el artículo publicado y favorece y permite la difusión del mismo bajo licencia Creative Commons Reconocimiento-CompartirIgual 4.0 Internacional (CC BY-SA 4.0). Esta licencia permite copiar, usar, difundir, transmitir y exponer públicamente el artículo, siempre que siempre que se cite la autoría y la publicación inicial en Anales del Sistema Sanitario de Navarra, y se distinga la existencia de esta licencia de uso.
